113. Muscular dystrophy Clinical trials / Disease details
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05689164 (ClinicalTrials.gov) | April 14, 2023 | 9/1/2023 | A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy. | Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study | Duchenne Muscular Dystrophy | Biological: fordadistrogene movaparvovec | Pfizer | NULL | Not yet recruiting | 0 Years | N/A | Male | 250 | Phase 3 | NULL |
| 2 | NCT05429372 (ClinicalTrials.gov) | August 8, 2022 | 8/10/2021 | Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy | A PHASE 2, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND DYSTROPHIN EXPRESSION AFTER FORDADISTROGENE MOVAPARVOVEC (PF-06939926) ADMINISTRATION IN MALE PARTICIPANTS WITH EARLY STAGE DUCHENNE MUSCULAR DYSTROPHY | Muscular Dystrophy, Duchenne | Genetic: PF-06939926 | Pfizer | NULL | Recruiting | 2 Years | 3 Years | Male | 10 | Phase 2 | United States;Australia |